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INTRODUCTION 
  
INTRODUCTION 
Chronic Obstructive Pulmonary Disease, a very common disease, 
and it is the 4th leading cause of death in worldwide. In India, it is the 2nd 
most common lung disorder after pulmonary tuberculosis. It is one of 
the preventable and treatable disease. Smoking and air pollution are the 
main risk factors. 
 COPD is a systemic disease, because inflammation is not only 
involved in lung airways, but also seen in systemically. So COPD is 
associated with variety of extra pulmonary manifestations. Most 
important systemic manifestation is Cardiovascular diseases, which are 
more frequently common in patients with COPD, and it is responsible 
for high mortality and morbidity. Among COPD patients, 
Cardiovascular disease is responsible for 50% of hospitalization and 
20% of deaths. 
Inflammation is one of the systemic manifestations of COPD and 
provides a hypothesis to explain the relationship between cardiovascular 
risk and airflow limitation. COPD increases the risk of cardiovascular 
disease regardless of age, sex, smoking status.  
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COPD is well known disease that can cause greater effect on right 
sided heart due to development of pulmonary hypertension. Cor 
pulmonale and right heart failure are the usual manifestations. But 
COPD increases the risk of developing other Cardiovascular 
manifestations are Ischemic Heart Disease,  congestive heart Failure, 
arrhythmias, most commonly AF, etc. 
Recent studies show that there is high prevalence Left Ventricular 
Diastolic Dysfunction is COPD patients even in the absence of ischemic 
heart disease. Diastolic heart failure prolongs the hospitalization and 
increases the risk of morbidity and mortality in COPD patients.  
 
  
 
 
 
 
 
  
AIMS AND 
OBJECTIVES 
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AIMS AND OBJECTIVES 
 To assess the left ventricular diastolic function in COPD  patients 
using Echocardiogram. 
 To detect the presence of left ventricular diastolic dysfunction in 
all stages of COPD (GOLD Stages). 
 
 
 
 
 
 
 
 
 
 
  
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
Chronic obstructive pulmonary disease and its components has 
been known to humans for over 200 years. First, Bonet described the 
COPD as “voluminous lungs” in 1679 and Morgagni reported cases of 
“turgid” lungs in 1769.1 
In 1984, Badham (British Physician) identified bronchiolitis and 
chronic bronchitis and he used the term ‘catarrh’ that indicates chronic 
inflammation of the mucous membrane.2 
Laennec (the physician and inventor of the stethoscope) described 
“emphysema” in his Treatise of diseases of the chest in 1821. He 
recognized that emphysema lungs were excessively inflated.3 
In 1846, John Hutchinson invented the spirometer, and that device 
measured vital capacity and In 1947, Robert Tiffeneau introduced the 
concept of timed vital capacity and created complete diagnostic 
spirometer.4 
Oswald explained the clinical features of chronic bronchitis in 
1953. Barach and Bickerman wrote the first comprehensive text book of 
“Pulmonary emphysema” in1956 and also described about the 
treatment. 5 
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In 1976, Charles Fletcher wrote about the natural history of 
COPD and also indentified the link between smoking the accelerated 
rate of decline in lung function.6 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
COPD is the disease of airflow limitation which is not fully 
reversible which includes  
1. Emphysema  
2. Chronic bronchitis 
DEFINITION OF CHRONIC BRONCHITIS (by British Medical 
Research Council)   
Chronic bronchitis is defined as “Daily productive cough for at 
least three consecutive months for more than two successive years”.7 
DEFINITION OF EMPHYSEMA (by National Heart, Lung and 
Blood Institute in 1984)   
 Emphysema is a condition of the lung which is characterized by 
“abnormal, permanent enlargement of airspaces distal to the terminal 
bronchiole, accompanied by the destruction of their walls, and without 
obvious fibrosis”8 
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GOLD definition of COPD   
COPD is a common preventable and treatable disease, 
characterized by “persistent airflow limitation, that is usually 
progressive and associated with an enhanced chronic inflammatory 
response in the airways and the lung to noxious particles or gases. 
Exacerbations and comorbidities contribute to the overall severity in 
individual patient”.9 
EPIDEMOLOGY 
 COPD – 2nd most common lung disorder after tuberculosis in 
India 
 More common in middle aged patients. Rare below age of 35 
 Equally prevalent in rural and urban areas 
 Prevalence  at global level is approximately 9-10%10 
 In India prevalence is 3.49%11 
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RISK FACTORS 
 
Genetic factors: 
Αlpha1-antitrypsin deficiency – strongest genetic factor for 
development of COPD.12 Alpha 1-antitrypsin is a major circulating 
serine protease inhibitor, which is produced by liver. 
 Other genes related to development of COPD are 13 
 Alphanicotinicacetylcholine receptor 
 Hedgehog-interacting protein gene 
 FAM13 gene 
 Gene encoding MMP12 
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Environmental factors 
Tobacco smoking is the main etiological risk factor for 
obstructive pulmonary disease14.  
Other environmental factors, which increase the risk of COPD are  
 occupational exposure to dusts and fumes 
 outdoor air pollution16 
 exposure to biomass smoke  
 second-hand smoke inhalation23 
Adult cigarette smokers have following effects while comparing 
with non-smokers17 
 have high risk respiratory infections and symptoms 
 greater loss of lung density  
 a greater reduction rate of FEV1 
 greater mortality rate  
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Infections and exacerbations 
Recurrent severe respiratory infections in childhood usually 
associated with increased risk of COPD in adulthood.18 
  In established COPD, recurrent infections and exacerbations can 
lead to progression of disease and excessive decline in FEV1
19  
Tuberculosis also one of the risk factor for COPD, mainly due to 
airflow limitation from scarring.20 
Asthma and Bronchial Hyperreactivity 
COPD and Asthma are the two different diseases with variable 
overlap. Asthma may be also one of risk factor for development of 
COPD. 
Patients with asthma have 12 fold higher risk for occurring 
COPD. 
PATHOGENESIS 
There are multiple mechanisms involved in pathogenesis of 
COPD. Following theories are proposed in COPD.21 
10 
 
 
 
Pathogenesis of COPD and CHRONIC BRONCHITIS 
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PATHOLOGY 
 Cigarette smoking affects large airways, small airways(<2mm) 
and alveoli. 
 In COPD - major site of obstruction is small airways24 
Chronic bronchitis  
 hypertrophy of mucus secreting glands and goblet cell 
hyperplasia in large airways 
 Reid index increases to 0.52 (normal 0.44) 
 Reid index is defined as “ratio of thickness of submucosal 
glands to that bronchial wall” 
 involvement small airways (chronic bronchiolitis) – major site 
of increased resistance in COPD  
Emphysema 
 Destruction of alveoli, alveolar ducts and respiratory bronchioles, 
which are the gas exchanging air spaces, lead to decrease the lung 
elastic recoil, that results in reduction of maximal expiratory airflow. 
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PATHOLOGICAL FEATURES OF COPD 
 Destruction of alveolar tissue and small airways 
 Airway wall inflammation 
 Edema and fibrosis28 
 Intraluminal mucus 
 
 
Figure 1. Pathology of Chronic Bronchitis and Emphysema 
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PATHOLOGICAL TYPES OF EMPHYSEMA 
Centriacinar: 
o Involves proximal part  of acini (respiratory bronchiole) 
o Associated with cigarette smoking 
o Upper lobes and superior segments of lower lobes are more 
commonly involved. 
Panacinar: 
o Uniformly enlarged all part of acini from respiratory 
bronchiole to alveoli 
o Common in Αlpha1-antitrypsin deficiency 
o Predominantly occurs in lower lobes. 
Paraseptal: 
o Involves distal portion of acini (sparing of proximal 
portion) 
o Usually occurs adjacent to pleura  
o Progressive enlargement to form bullae 
o More prone to spontaneous pneumothorax 
14 
 
Irregular emphysema: 
o Irregular involevement of acini and almost always 
associated with scarring 
o This pattern common in Tuberculosis. 
Figure 2. Pathological types of emphysema 
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PATHOPHYSIOLOGY 
Airflow limitation and air trapping: 
o The extend of pathological changes in small airways is 
strongly interrelated with FEV1 and FEV1/FVC ratio 
o Accelerated reduction in FEV1 – characteristic of COPD29  
o Hyperinflation of lungs occur as result of progressive trapping 
of air in the peripheral airways during expiration  
o Hyperinflation leads to decrease in inspiratory capacity and 
also increases functional residual capacity, Tidal volume 
especially during exercise (also called dynamic hyperinflation) 
which results in progressive dyspnea and limitation of physical 
activity 
Gas Exchange abnormalities: 30 
o Hypoxemia 
o Hypercapnea 
Usually occurs in late stages of COPD (FEV1 <50%) 
CLINICAL FEATURES: 
3 cardinal symptoms are  
 Cough 
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 Sputum production 
 Exertional dyspnea 
PHYSICAL FINDINGS 
 Early stages – normal physical finding 
 Nicotine stain on fingernails (current smokers) 
 Barrel shaped chest (sign of hyperinflation) 
 Working accessory muscles 
 Sitting in tripod position (to facilitate actions of 
sternocleidomastoid, scalene, intercostal muscle) – 
characterisitic position  
 Patients with emphysema are called Pink puffers , they are thin 
and non-cyanotic at rest, and prominent action of accessory 
muscles  
 Blue bloaters –  heavy and cyanotic (Chronic Bronchitis) 
 Expiratory wheeze on auscultation 
Sings of advanced disease: 
 Cachexia22 
 Significant weight loss 
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 Bitemporal wasting 
 Diffuse loss of subcutaneous adipose tissue 
 Hoover sign – paradoxical inward movement of rib cage 
with inspiration 
 Sings of right heart failure – edema, ascites, raised jugular 
venous pulse 
Difference between features of chronic bronchitis and emphysema 
 
Emphysema and chronic bronchitis frequently co-exists because 
both share common etiology and risk factors. 
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DIAGNOSIS: 
Hallmark of COPD is airflow obstruction, which can be detected 
by Pulmonary Function testing. 
PULMONARY FUNCTION TESTING (SPIROMETRY): 
 Spirometry should be performed after the short-acting 
bronchodilator by inhalational route 
 Presence of airflow limitation is confirmed by post-bronchodilator 
FEV1/FVC < 0.70 
31 
 Severity of COPD can be assessed by FEV134 
 The FEV1 is often used to assess the clinical course and response 
to therapy.32 
 The total lung capacity, functional residual capacity, and residual 
volume often increase to supernormal values that indicates lung 
hyperinflation and air trapping.33 
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Figure 3. Spirometric evaluation 
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IMAGING: 
o Chest x ray 
o HRCT chest 
Radiological findings associated with COPD are 
 Prominent bronchovascular markings 
 Hyperinflated lung fields with diaphragmatic flattening 
 Hyperlucency 
 Increased retrosternal airspace on the lateral radiograph 
 Presence of bullae 
 Tubular heart 
HRCT chest  
 superior to detect the findings of COPD than Chest X ray37  
 useful for assessment of surgical management35 
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Figure 4a. Picure A: large lung volumes with hyperlucency 
Figure 4b. prominent retrosternal clear space of lateral radiograph with 
flattening of diaphragm 
ELECTROCARDIOGRAM: 
ECG changes in COPD are36 
 Right axis deviation 
 P-Pulmonale 
 RVH pattern 
 Right bundle branch block 
 Low voltages complexes 
 Poor progression of R wave 
 Arrhythmias  
22 
 
ECHOCARDIOGRAPHY: 
Assessment of cardiac status 
pulmonary hypertension 
cor pulmonale 
  RV dysfunction 
  LV systolic function and ejection fraction  
  LV diastolic function 
PULSE OXIMETRY AND ABG: 
 Pulse oximetry is usually used to asses O2 saturation in  
Stable patients with FEV1<35 
Signs of respiratory failure 
 ABG should be assessed when SpO2 <92%
147 to identify 
  Hypoxemia (type I respiratory failure)  
Hypercapnea (type II respiratory failure) 
ALPHA-1 ANTITRYPSIN SCREENING: 
Indications for screening  
 Young patients (<45 years) 
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 Lower lobe emphysema 
 Family history 
 No smoking history 
 Serum alpha-1antitrypsin levels below 15-20% of normal range is 
considered as alpha-1antitrypsin deficiency 
EXERCISE TESTING: 
o 6-minute walk test (6MWT) - frequently employed exercise 
test  
o 6-minute walk distance(6MWD) -  The distance that a 
patient can walk in 6 minutes 40 
o Health status impairment can be assessed by exercise 
testing and it is one of the prognostic predictor. 
o 6MWD is a component of the BODE mortality index41 
o It can be used to monitor improvement in quality of life, 
exercise capacity after pulmonary rehabilitation 
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STAGES OF COPD (GOLD STAGES): 
Based on Post bronchodilator FEV1  
 
Early Stages – Stage I & II 
Late Stages – Stage III & IV 
BODE INDEX: 
 Multidimensional grading system which predicts the mortality 
and survival of the patients with COPD.41 
25 
 
 
 
SEVERITY ASSESSMENT: 
By Combined Assessment  
 Assess symptoms 
 Assess degree of airflow limitation using spirometry 
 Assess risk of exacerbations 
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Assessment of symptoms: 
o Modified Medical Research Council questionnaire for 
breathlessness43 
o COPD assessment test  
 
 
COPD Assessment Test: 
 Used to asses health status impairment in COPD 42 
 8 measures are used in this test 
 Score varies from 0-40 
27 
 
CAT test chart 
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GOLD classification system44 
 
Groups of COPD patients (according to GOLD 2015 update) 
Group A – Low risk and Less symptoms 
o GOLD stage I or II 
o No of exacerbation/year 0-1 
o No hospitalization 
o CAT score <10 
o mMRC grade 0-1 
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Group B – Low risk and More symptoms 
o GOLD  stage II or II 
o mMRC grade 0  > 2 
o CAT score >10 
o No of exacerbation/year 0-1 
o No hospitalization 
Group C – High risk and Less symptoms 
o GOLD stage III or  IV 
o mMRC grade 0-1 
o CAT score <10 
o 2 or more exacerbation/year 
o 1 or more hospitalization 
Group D – High risk and More symptoms 
o GOLD  stage III or IV 
o 2  or more exacerbation/year 
o 1 or more hospitalization 
o CAT score >10 
o mMRC grade 0  > 2 
30 
 
TREATMENT 
  Combined approach by  
Smoking cessation 
 Pharmacological therapies 
 Non pharmacological therapies 
 Surgical management 
SMOKING CESSATION 
 most important factor in the management of COPD, since it 
the main etiological factor 
 Smoking cessation slows the progression of reduction in 
FEV1
45. 
 Multimodality approach including Counseling for smoking 
cessation and pharmacological therapies is the effective 
method to treat tobacco addiction 
 It is the one of component of Pulmonary rehabilitation 
 Improves the survival and outcome of COPD patients 
 greater reduction in prevalence of pulmonary complications 
as well as systemic manifestations 
31 
 
Pharmacological therapy for smoking cessation 
 
 
 
 
 
 
 
 
 
PHARMACOLOGICAL THERAPIES 
 Bronchodilators 
 Beta 2 agonists 
 Methylxanthines 
 Anticholinergics 
 Inhaled corticosteroids 
PDE-4 inhibitors   
Mucolytic and antioxidant agents 
Anti tussives 
32 
 
 
 
SABA – Short acting beta2 agonists 
LABA – Long acting Beta 2 agonists 
SAMA – Short acting antimuscarinic agents 
LAMA – Long acting antimuscarinic agents 
ICS – Inhalational Corticosteroids 
PDE- 4 inh – Phosphodiesterase 4 Inhibitors 
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Bronchodilators 
 Increase FEV1 by altering airway smooth muscle tone 
 Reduce dynamic hyperinflation during exercise was well as rest48 
Improve exercise performance47 
Inhaled therapies are preferred 
Long acting inhaled bronchodilators are more effective and more 
symptom relief and also more convenient 
Beta2 agonists 
 Short acting 
 Salbutamol, Levalbuterol, Fenoterol, Terbutaline 
 Long acting 
 Salmeterol, Formoterol, Arformoterol, Tulobuterol, Indacaterol 
 Side effects – tremor, tachycardia, hypokalemia 
Anticholinergics 
 Short acting - Ipratropium bromide, oxitropium bromide 
 Long acting – glycopyrronium bromide, tiotropium, aclidinium 
bromide, umeclidinium 
 Side effects – dryness of mouth 
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Methylxanthines 
 Aminophylline, theophylline 
 Theophylline – most commonly used 
 Less effective and less tolerated than long acting inhaled 
bronchodilators 
 Low dose theophylline reduces exacerbations usually but there is 
post-bronchodilator  improvement in lung function 
Use of combination with different pharmacological classes of 
bronchodilators usually improve efficacy of therapy and also decreased 
side effect profile. It is better than increasing the dose of a single 
bronchodilator.49 
Inhaled corticosteroids 
 Drugs – budesonide, beclomethasone, fluticasone 
 Regular treatment with ICS therapy  in COPD patients with an 
FEV1 < 60%, improves the lung function and respiratory 
symptoms, and also improves the quality of life and reduces 
frequency and duration of exacerbations.51 
 Inhaled steroids treatment withdrawal may lead to acute 
exacerbations in some patients 
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 There is increased  risk of lung infection like pneumonia 
associated with inhalational steroid therapy 
 Adverse effects – hoarse voice, oral candidiasis, skin bruising 
 An ICS combined with a LABA is more effective  in  
 reducing acute exacerbations in severe COPD patients52 
 improving health status and lung function  
Oral corticosteroids 
 Chronic treatment with systemic corticosteroids should be 
avoided because of an unfavorable benefit-to-risk ratio 
Roflumilast  
o inhibitor of phosphodiesterase-4 enzyme  
o It inhibits the break down of intracellular cAMP and there 
by it  reduces inflammation   
o Dose once a day schedule (500 mg)  
o Roflumilast along with long-acting β2 agonists  reduce 
exacerbations in COPD53 
o Adverse effects - nausea, diarrhoea, sleep disturbances, 
headache, and weight 
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Vaccines: 
 Recommended vaccination in COPD are 
 Influenza vaccine 54 
 Pneumococcal polysaccharide vaccine55 
 Effects of Vaccination in COPD patients 
 reduce respiratory tract infections that leads to prevention of 
acute exacerbations which requires hospitalization and there is 
definite morbidity and mortality benefits 
 decrease the prevalence of community acquired pneumonia   
Oxygen therapy: 
 Long-term oxygen therapy increase survival of COPD patients 
with respiratory failure. LTOT means oxygen therapy with more than 15 
hours/day. 
 Indications for LTOT:  
 SaO2 less than 88% (or) PaO2 less than 55 mm Hg with or 
without hypercapnia for two times in a three week period.  
 PaO2 between 55 mm Hg and 60 mm Hg with presence of 
Pulmonary arterial hypertension, Congestive cardiac Failure 
and Secondary Polycythemia (Hct >55).56 
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PULMONARY REHABILITATION: 
One of the main component in the managment of COPD.  
The pulmonary rehabilitation programme includes 
      
The major benefits of the rehabilitation programme are: 
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Pulmonary rehabilitation programme with exercise training of at 
least four weeks has been shown that there is significant improvement in 
health related quality of life and mortality.57 
Nutritional support: 
 BMI is one of the independent prognostic and mortality 
predictor in COPD patients. 
 Low Body mass index and nutritional depletion are the 
factors associated with poor prognosis. 
 Ghrelin, Growth hormone releasing peptide, decreases the 
utilization of peripheral fat and stimulates good appetite by  
GH-independent mechanisms, which lead to positive 
energy balance 
 Ghrelin level was decreased in COPD 
 Nutritional supplementation should be a part of integrated 
rehabilitation programme with exercise training, because 
nutritional support  have significant role in the management 
of COPD.60 
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PATIENT EDUCATION: 
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SURGICAL MANAGEMENT  
Lung volume reduction surgery (LVRS): 
LVRS not only increase exercise capacity but also improve the 
Quality of Life in COPD patients, most benefit in patients with upper 
lobe emphysema and with poor exercise capacity. 
It should not be performed in patients with non-upper lobe 
emphysema and with high baseline exercise capacity, since mortality is 
increased in these patients. So they are poor candidates for LVRS58 
Lung transplantation: 
 Transplantation of lung is another option in patients with  FEV1  
< 25%  and/or paCO2  > or = 55 mm Hg.  
Survival rates after lung transplantation approximately  
80% at one year 
50% at five years 
35% at ten years 
Bronchiolitis obliterans - long-term complication of lung 
transplantation which can result in decline of lung function.59 
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PULMONARY COMPLICATIONS OF COPD 
 Recurrent episodes of acute exacerbation by viruses and 
bacteria 
 Pneumothorax 
 Chronic and Acute on Chronic respiratory failure 
 Pulmonary artery hypertension 
 Cor pulmonale 
 Right heart failure 
ACUTE EXACERBATIONS: 
Definition:  
Acute exacerbation is defined as “acute event characterized by a 
worsening of the patient’s respiratory symptoms that is beyond normal 
day to-day variations and leads to a change in medication” 61 
Triggers: 
 Viral  or bacterial infections – most common62 
 Air pollutants 63 
 30% - no cause  
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Frequent exacerbations is defined as “two or more 
exacerbations per year”64 
 Management is challenging one for frequent exacerbators. 
Cardinal features of exacerbations 
Increase in dyspnoea, sputum volume, sputum purulence  
Common pathogens involved in acute exacerbation are 
 Streptococcus pneumoniae  
 Haemophilus influenzae 
 Pseudomonas aerugenosa 
 Moraxella catarrhalis 
Differential diagnosis of COPD exacerbations  
o Congestive cardiac failure 
o Pneumothorax 
o Pneumonia  
o Pulmonary embolism 
o Cardiac arrhythmias 
o Pleural effusion 
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Treatment of exacerbations  
 Bronchodilators 
 Corticosteroids 
 Antibiotics 
 Inhalational short-acting bronchodilators with β2-agonists and 
anticholinergics should be preferred in exacerbation65 and given 
either by nebulizers or by metered-dose inhalers.  
 Methylxanthines (theophylline or aminophylline i.v.) can be used 
if inadequate response to inhaled short-acting bronchodilators66.  
 Systemic corticosteroids   
reduce risk of  treatment failure, early relapse 
shortens recovery time and hypoxemia67 
decrease length of hospital stay 
Oral prednisolone 30-40 mg daily for 10-14 days 
Nebulized budesonide is an alternative 
 Supplemental O2 therapy to maintain SaO2 88 to 92%. 
 Mechanical ventilation if needed 
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Prevention of  exacerbation 
o Smoking cessation 
o Influenza and pneumococcal vaccination 
o Pulmonary rehabilitation 
o Knowledge about current therapy and inhaler technique 
o Treatment with long acting inhaled bronchodilators 
 
Effects of exacerbations in the course of disease 
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PULMONARY HYPERTENSION 
Usually develop in the late course of COPD. 
Mechanisms are 
 hypoxic vasoconstriction of small pulmonary arteries  
 endothelial dysfunction results from Inflammation   
 loss pulmonary capillary bed in emphysema increases pressure 
in pulmonary circulation 
Pulmonary hypertension can progress to Cor Pulmonale and Right Heart 
Failure 
SYSTEMIC MANIFESTATIONS OF COPD: 
Patients with COPD may have variety of comorbid illness due to 
its systemic nature of disease. Following systemic manifestations are 
reported with COPD 
 Cachexia: loss of fat-free mass 
 Skeletal muscle wasting 
 Pulmonary hypertension 
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 Congestive cardiac failure 
 Lung cancer (small cell, nonsmall cell) 
 Ischemic heart disease 
 Osteoporosis 
 Normocytic anaemia 
 Obstructive sleep apnoea 
 Diabetes 
 Metabolic syndrome 
 Depression 
Figure 5. Pathogenesis of systemic manifestations of COPD 
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Mechanism of systemic manifestation: 
 There are two theories for explaining systemic manifestations 
1. Spillover of inflammation from the lung into the systemic 
compartment 
2. Pro-inflammatory phenotype – systemic inflammation occurs 
independent of pulmonary inflammation. 68 
Pathological mechanisms of the Systemic Inflammation 
1. Smoking causes systemic inflammation by promoting vascular 
endothelial dysfunction and by generating oxidative stress. 
These changes also occur even in passive smokers and 
smokers of only a few pack-years.69 
2. Hypoxia leads to generation of Hypoxia inducible factor-1. 
This factor activates numerous genes involved in 
erythropoiesis, energy metabolism, angiogenesis, vascular 
remodelling, inﬂammation and cell proliferation70.  
Hypoxemia results in elevation of TNF-α level, and its 
elevated levels were associated with the severity of  
hypoxemia.  Domiciliary oxygen therapy (LTOT) improves  
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survival of patients, since it decreases systemic inflammation 
by reducing the hypoxemia and related changes. 
3. Adipokines were also demonstrated in COPD patients and its 
association with development of comorbidities. Circulating 
leptin, one of the factor which promote systemic inflammation 
in stable COPD patients. Increased leptin levels may lead  to 
decline in pulmonary function  in smokers with COPD, 
independent of obesity 71 
4. COPD  induces the development of anti-elastin antibodies, 
which is responsible for auto immunity that explain the 
progression of COPD  even after stopping of smoking.72 
5. Accelerated lung ageing occurs in COPD may also responsible 
the systemic inflammation and development of co morbidities. 
COPD is a state of oxidative stress which can cause telomere 
shortening that results in increased ageing process in the lung 
and other systems.73 
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CARDIOVASCULAR MANIFESTATIONS OF COPD: 
 Coronary artery disease 
 Left ventricular diastolic dysfunction 
 Congestive heart failure 
 Atrial fibrillation 
 Ventricular arrhythmias 
Poor lung function is the main risk factor for LV diastolic 
dysfunction, atrial fibrillation, and ventricular dysarrhythmias  
Coronary artery disease: 
 COPD and CAD are closely related, there is 3-fold cardiovascular 
risk in COPD while compared to other population  
 Concomitant involvement of COPD and CAD increase the 
morbidity and mortality 
 Systemic inflammation in COPD is the important pathogenesis 
for development of atherosclerosis and ischemic heart disease.74 
 Airflow limitation significantly increases the risk myocardial 
infarction and its related death in patients with COPD. This can 
be occur irrespective of age, sex and smoking history75 
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 Ischemic heart disease in COPD patients can be managed 
according to IHD guidelines in the presence of COPD.  Treatment 
with Cardioselective Beta blockers is considered safe. 
Heart failure: 
 It is another common co morbidity in patients with COPD.  
 30% of stable COPD  patients have some degree of Heart failure 
 Acute heart failure and acute exacerbation of COPD often 
coexists, that increases the morbidity and mortality 
 Heart failure in COPD can be managed according to usual HF 
guidelines. Selective beta1 blockers significantly improves the 
survival76. Bisoprolol is superior to carvedilol on respiratory 
parameter. 
Atrial fibrillation: 
 AF is the most common arrhythmia encountered in COPD 
 Increases the breathlessness and disability, when coexists with 
COPD. 
 Treatment according to usual AF guidelines 
 Cardioselective beta blockers are preferred, when beta blockers 
are used. 
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LV DIASTOLIC DYSFUNCTION AND COPD: 
There many mechanisms that explain the presence of left 
ventricular diastolic dysfunction in COPD 
 Chronic hypoxemia results in intracellular calcium transport 
disturbances that leads to abnormalities of myocardial 
relaxation77,78 
 Presence of cor pulmonale (secondary to pulmonary 
hypertension) results in interventricular septum deviation 
toward left ventricle. These changes may lead to alteration in 
left ventricular geometry and impairs the ventricular filling.80 
  Presence of emphysema and hyperinflation  impairs  left 
ventricle filling.81 Cardiac  function may be impaired as a 
result of  raised intrathoracic pressures which may lead to 
decrease in preload and increase in left ventricular afterload.82 
 Airflow limitation and Systemic Inflammation which are 
responsible for atherosclerotic plaque formation that can lead 
to myocardial ischemia and left ventricular diastolic 
dysfunction.83 
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LEFT VENTRICULAR DIASTOLIC DYSFUNCTION:  
LV diastolic function  can be asses by Doppler echocardiography 
By assessing mitral inflow signal 
  
E wave – early diastolic LV filling 
A wave – late diastolic LV filling due to atrial contration 
DT – deceleration time of  E wave 
IVRT  - Isovolumetric relaxation time 
 
Grading of LV diastolic dysfunction: 
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Figure 6. Grades of LV diastolic dysfunction 
 
 
Normal diastolic function 
 E-wave is taller than the A-wave.  
The E/A ratio will be between 1 and 2.  
The shape of the E-wave is quite symmetrical and the normal 
deceleration time is between 150 ms and 200 ms.  
IVRT is 50 - 100 ms. 
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Impaired relaxation - grade I diastolic dysfunction: 
 Magnitude of the E-wave  decreases (stiff ventricle impairs 
early ventricle filling) 
 IVRT increases (> 100 ms) 
 A-wave will be larger ( due to effective atrial contraction)  
 E-wave (E/A ratio < 1) 
 DT will also be prolonged (≥ 240 ms). 
Pseudo normal filling pattern - grade II diastolic dysfunction: 
 Ongoing diastolic dysfunction may lead rise in LA pressure  
 Pressure gradient between LA and LV increases, so there is 
increased force to fill the ventricle during early diastole. This lead 
to increase in size of the E-wave compared to A wave  
 E/A ratio become to 0.8 - 1.5. 
 DT and  IVRT (< 90 ms)  also decrease 
 This looks similar to “normal” diastolic function and so referred 
as “pseudonormal” 
 Valsalva maneuver unmask elevated filling pressures by 
decreasing the preload. So there is reversal of the pattern to  grade 
I LVDD during the maneuver.  
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Reversible restrictive filling pattern - grade III diastolic 
dysfunction: 
 Progressive and further rise in filling pressure leads to further 
increase the pressure gradient between LA and LV.   
 E-wave become more tall, and the A-wave become short.  
 The E/A ratio  ≥ 2 
 Short  DT (<160 ms) and IVRT (≤ 80 ms). LV filling starts early 
and also terminate quickly due to elevated filling pressure 
 Valsalva maneuver reverses the restrictive filling to a 
“pseudonormal” pattern (grade II). 
Irreversible restrictive filling Pattern - grade IV diastolic 
dysfunction: 
 It is the most severe form of dysfunction  
 Valsalva maneuver is unable to reverse the pattern to a 
pseudonormal one. This is the differentiating feature between 
grade III and IV 
 These patients are usually symptomatic and have advanced forms 
of heart failure. 
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EFFECTS OF LV DIASTOLIC DYSFUNCTION IN COPD: 
 LV diastolic dysfunction may be asymptomatic or it can present 
with classical heart failure symptoms - diastolic heart failure. 
 more common in older women 
 prevelance increases with age83 
 Its prevalence also increases with stages of COPD. More common 
in later stages of COPD84 
 Other risk factors for developing diastolic heart failure are88 
o Hypertension 
o Diabetes mellitus 
o Obesity 
o Ischemic heart disease  
 Diastolic heart failure increases the mortality and morbidity when 
coexists with COPD 
 Left ventricular diastolic dysfunction increases risk of 
exacerbation and prolongs the hospitalization 87 
 Mortality rates of COPD with left ventricular diastolic 
dysfunction 
 29% at one year 
 65% after five years 86 
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 It is very essential to exclude heart failure during acute 
exacerbation of COPD.85 
DRUGS ASSOCIATED WITH IMPROVED CARDIOVASCULAR 
OUTCOME 
o Statins 
o ACE inhibitors 
o Beta blockers 
Role of statins: 
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Statins not only reduce cholesterol but also exert several other 
pharmacological actions including 89 
 anti-inflammatory  
 antioxidant 
 immunomodulation 
Statins have favourable effects on cardiovascular disease  
and improves the outcome of COPD patients associated with  
co morbidities.90 
ACE inhibitors: 
 ACEIs are used to treat heart Failure and hypertension in COPD. 
 ACE inhibitors have been shown that to reduce pulmonary 
hypertension. 
 It may reduce exacerbations and has mortality benefits in patients 
with COPD.91 
 May  reduce pro-inflammatory effects of angiotensin.92 
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Beta blockers: 
Long-term cardioselective beta-blocker are safe and well-
tolerable in patients with COPD. 
Beta-blocker co-prescription in COPD have favourable cardio-
vascular outcome and improves the survival.76 
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MATERIALS AND METHODS 
SOURCE OF DATA: 
Patients admitted in Institute of Internal Medicine, Madras 
Medical College and Rajiv Gandhi Government General Hospital, 
Chennai-3, diagnosed to have Chronic Obstructive Pulmonary Disease, 
fulfilling the inclusion and exclusion criteria were included in the study 
group. 100 such patients were taken up for this study. 
STUDY DESIGN: 
A hospital based observational study 
STUDY DURATION: 
6 months: March 2015-August 2015 
INCLUSION CRITERIA: 
Proven cases of chronic obstructive pulmonary disease by 
clinical, imaging, and Pulmonary Function Test. 
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EXCLUSION CRITERIA: 
 Patients with co morbid illness Diabetes Mellitus, Hypertension, 
Chronic Kidney Disease 
 Coexisting intrinsic heart disease like coronary artery disease, 
valvular heart diseases 
 Patients with coexisting with other lung pathologies 
DATA COLLECTION AND METHODS: 
Data was collected in a pretested proforma from eligible patients. 
100 patients were selected on the basis of simple random sampling. 
They were subjected to detailed history taking and clinical examination. 
The following investigations were done. 
 Chest X-ray 
 Electrocardiogram 
 Pulmonary function test 
 Echocardiogram 
PFT – Pulmonary function test: 
All patients were subjected to PFT using spirometer in the 
standing position according to standard procedures. Following 
measurements were obtained  
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o Forced expiratory volume in one second (FEV1), 
o Forced vital capacity (FVC), 
Predicted values for each of the parameters were obtained from 
standardized references. 
ECHOCARDIOGRAPHY: 
A 2-D transthoracic echocardiography was done for all patients to 
asses chambers size, systolic and diastolic functions of LV, presence of 
Pulmonary hypertension and RV function. LV diastolic function was 
assessed and graded by Doppler echocardiography by assessing mitral 
inflow signal, E/A ratio,  deceleration time of  E wave (DT), 
Isovolumetric relaxation time (IVRT). 
STASTICAL METHODS APPLIED: 
Datas were analysed using the SPSS software. Statistical 
significance was indicated by the Chisquare test. Variables were 
considered to be significant if p<0.05. 
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OBSERVATION AND RESULTS 
Table1.  AGE DISTRIBUTION 
Age group (years) Frequency Percent 
 
 <40 2 2.0 
41-50 20 20.0 
51-60 39 39.0 
> 60 39 39.0 
Total 100 100.0 
 
 Most cases of COPD occur in the age group 51-60 years and 
above 60 years 78% of cases are above 50 years 
 
2%
20%
39% 39%
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
UPTO 40 YRS 41-50 YRS 51-60 YRS ABOVE 60 YRS
AGE DISTRIBUTION 
UPTO 40 YRS 41-50 YRS 51-60 YRS ABOVE 60 YRS
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Table 2. SEX DISTRIBUTION 
Sex Frequency Percent 
 
MALE 81 81.0 
FEMALE 19 19.0 
Total 100 100.0 
 
 
Among 100 patients 81% were male, 19% were female 
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Table 3. Smokers vs Nonsmokers 
 Frequency Percent 
 
NON SMOKERS 23 23.0 
SMOKERS 77 77.0 
Total 100 100.0 
 
 
In our study, majority of COPD patients in our study are smokers 
(77%). 
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Table 4. DURATION OF SYMPTOMS 
Duration of symptoms 
(years) 
Frequency Percent 
 
< 5  54 54.0 
5-10 32 32.0 
>10  14 14.0 
Total 100 100.0 
 
 
In our study, majority of patients had duration of symptoms  
<5 years (54%). Patients with symptoms more than 10 years are least 
common. 
DURATION OF SYMPTOMS
UPTO 5 YRS
5 to 10 YRS
ABOVE 10 YRS
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Table 5. Stages of COPD (GOLD Stages) 
Stages Frequency Percent 
 
I 16 16.0 
II 40 40.0 
III 30 30.0 
IV 14 14.0 
Total 100 100.0 
 
In our study among 100 patients, 16 patients were in stage I, 
 40 were in Stage II, 30 were in Stage III, 14 were in Stage IV.  
Most patients were in stage II and III (70%). Early stages (I &II) – 46%, 
Late stages (III&IV) – 54%. 
 
16%
40%
30%
14%
GOLD Stages of COPD
I II
III IV
 
68 
 
Table 6. Chest x ray findings 
CXR Findings Frequency Percent 
 
Prominent Bronchovascular 
markings 
34 34.0 
Hyperinflated Lungs  66 66.0 
Total 100 100.0 
 
 
 In our study, hyperinflated lung field is the common chest x ray 
findings. 66% of patients had  hyperinflated lungs. 44% had finding of 
Prominent Bronchovascular markings. 
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Table 7.  ECG FINDINGS 
ECG findings Frequency Percent 
P – Pulmonale 30 30.0% 
RVH 10 10.0% 
RAD 32 32.0% 
RBBB 12 12.0% 
PPRW 26 26.0% 
Low voltage complexes 18 18.0% 
 
Most common ECG finding in our study population is Right Axis 
Deviation (32%). P-Pulmonale found in 30% of patients. 
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Table 8. ECHO Findings 
ECHO findings Frequency Percent 
LV SYSTOLIC DYSFUNTION 6 6.0% 
LV DIASTOLIC DYFUNCTION 80 80.0% 
PULMONARY HYPERTENSION 50 50.0% 
DILATED RA/RV 30 30.0% 
RV  DYSFUNCTION 14 14.0% 
 
In our study, most common Echo finding is Left Ventricular 
Diastolic dysfunction, seen in 80% of patients.  50% patients had 
Pulmonary Hypertension.  Dilated Right Atrium and Ventricle seen in 
30% of patients. Right Ventricular Dysfunction seen in 14% of Patients. 
Left Ventricular Systolic Dysfunction seen in 6% of patients. 
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Table 9. Correlation between Patient’s Age and LV Diastolic 
Dysfunction 
Age group 
No. 
patients 
LV Diastolic 
Dysfunction 
Chi 
square 
P value 
Upto 40 yrs 2 0 
16.795* P<0.001 
41-50 yrs 20 12 
51-60 yrs 39 32 
Above 60 yrs 39 36 
Total 100 80 
 
CORRELATION COEFFICIENT  r =0.373* 
 
In our study, there is high prevalence of Left Ventricular diastolic 
dysfunction seen in patients above 60 years of age (92%). As age 
advances, prevalence of LV diastolic dysfunction increases. 
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Table 10. Correlation between duration of symptoms and LV 
Diastolic Dysfunction 
Duration of 
symptoms 
No patients 
LV diastolic 
dysfunction 
Chi 
square 
P value 
Upto 5 yrs 54 40 
4.238* 0.038 
5-10 32 26 
Above 10 yrs 14 14 
Total 100 80 
 
CORRELATION COEFFICIENT r =0.208* 
 
 In this study, prevalence of LV diastolic dysfunction increases 
when duration of symptoms increases. Patients with duration of 
symptoms above 10 years universally all had LV diastolic dysfunction.  
But patient with less years of symptoms also had high prevalence of LV 
diastolic dysfunction. 
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Table 11. Correlation between smoking status and LV Diastolic 
Dysfunction 
 No. patients 
LV Diastolic 
Dysfunction 
Chi square P value 
NON SMOKERS 23 15 
4.080* P<0.05   SMOKERS 77 65 
Total 100 80 
 
CORRELATION COEFFICIENT r =0.202* 
 
 
In this study, LV diastolic dysfunction  had been seen in both 
smokers and smokers. But smokers had high prevalence of LV diastolic 
dysfunction compared to non-smokers. 
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Table 12. Correlation between Chest X ray findings and LV 
diastolic dysfunction 
Chest X ray signs 
No. 
Patients 
LV diastolic 
dysfunction 
Chi square P value 
Hyper inflation 66 66 
48.529* P<0.001 
Prominent 
Bronchovasucular 
markings 
34 14 
Total 100 80 
 
 
 In our study, all patients with hyperinflated lungs on imaging had 
LV diastolic dysfunction (100%). 41% of  patients with prominent 
bronchovascular markings on chest x ray had LV diastolic dysfunction. 
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Table 13. Correlation between ECG findings and LV diastolic 
dysfunction 
 No. Patients 
LV Diastolic 
Dysfunction 
Chi 
square 
P value 
Normal ECG 50 34 
9.00 0.003 
Abnormal 
ECG 
50 46 
Total 100 80 
 
CORRELATION COEFFICIENT  r = 0.300* 
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In this study, 50% of patients had normal ECG finding and 50% 
had ECG changes of COPD. Patients with abnormal ECG had high 
prevalence of LV diastolic dysfunction (92%) compared to normal ECG 
(68%). This study shows that LV diastolic dysfunction can occur even 
in the absence of ECG findings of COPD. 
Table 14. Correlation between Stages of COPD and grading 
of LV diastolic dysfunction 
Stage of 
COPD 
No. 
Patients 
Grading of LV Diastolic  
Dysfunction 
Chi 
square 
P value 
I II III IV 
I 16 2 0 0 0 
112.175 P < 0.001 
II 40 34 0 0 0 
III 30 22 8 0 0 
IV 14 2 8 4 0 
Total 100 60 16 4 0 
 
CORRELATION COEFFICIENT  r = 0.791* 
In our study, Among 16 stage I COPD patients, only 2 were had 
grade I LV diastolic dysfunction, others had normal diastolic function. 
Among 40 stage II patients, 34 had grade I diastolic dysfunction. In 30 
stage III patients, 22 had grade I and 8 had grade II diastolic 
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dysfunction. In 14 stage IV patients, 2 patients had grade I, 8 patients 
had grade II and 4 patients had grade III LV diastolic dysfunction. There 
was significant correlation between stage of COPD and grading of LV 
diastolic dysfunction. 
Table 15. Correlation between with GOLD staging and  
LV diastolic dysfunction 
Gold Stage 
of COPD  
No.  
Patients 
LV Diastolic 
dysfunction 
Chi 
square 
P value 
I 16 2 
57.188 P<0.001 
II 40 34 
III 30 30 
IV 14 14 
Total 100 80 
 
CORRELATION COEFFICIENT  r = 0.610* 
In this study, among 100 patients, 80 had LV diastolic 
dysfunction. In stage I among 16 patients only 2 had diastolic 
dysfunction (12%). In stage II, among 40 patients 34 had LV diastolic 
dysfunction (88%). In stage III and IV all patients had LV diastolic 
dysfunction (100%). There was significant correlation between stages of 
COPD and left ventricular diastolic dysfunction. 
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DISCUSSION 
Our study was conducted in patients with chronic obstructive 
pulmonary disease to know the prevalence of left ventricular diastolic 
dysfunction. Our study population included 100 patients who were 
diagnosed as chronic obstructive pulmonary disease by clinical, imaging 
and pulmonary function test. All 100 patients were evaluated for cardiac 
status by electrocardiography and echocardiography and were screened 
for left ventricular diastolic dysfunction. Analysis was made to study the 
correlation between GOLD stages COPD and prevalence of left 
ventricular diastolic dysfunction by using Chi-square test. Following 
were the observations made from our study in COPD patients 
Age distribution: 
 Out of 100 patients, majority of patients were in the age group of 
above 50 years (78%). Only two cases were seen below 40 years. This 
showed that COPD is the disease occurs after 40 years of age. 
Sex distribution: 
 Out of 100 patients in this study, 81 patients were male, 19 
patients were female. Male to female ratio 4:1 
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Duration of symptoms: 
 In this study, majority of patients had duration of symptoms less 
than 5 years (54%). Duration of symptoms more than 10 years was less 
frequent (14%) 
Smoking status: 
 Out of 100 patients, 77 patients were smokers and 23 patients 
were nonsmokers. This showed that smoking is the main risk factor for 
chronic obstructive pulmonary disease. So the disease is common in 
males. 
Stage of COPD: 
 In our study, patients were staged according to GOLD 
classification. Spirometry was used to assess the stage. Stages were 
based on post bronchodilator FEV1. 16 patients were in stage I (16%), 
40 patients were in Stage II (40%), 30 patients were in stage III (30%), 
14 patients were in stage IV (14%). Majority of patients were in Stage II 
& III. 56 patients were in early stages (I&II), 44 patients were in late 
stages (III & IV).  
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Chest X findings: 
 Most common radiological finding in our study is hyperinflated 
lung fields, which is seen in 66% of patients. Prominent 
bronchovascular markings were seen in 34 patients. In this study, 
emphysematous lungs were more common than chronic bronchitis. 
ECG findings: 
 Out 100 patients in our study, 50 patients ECG were with in 
normal limits. 50 patients ECG showed signs of chronic obstructive 
pulmonary disease. Most common ECG findings were right axis 
deviation and P-Pulmonale (RAD – 32%, P-Pulmonale - 30%).  Next 
common findings were poor progression of R wave (26%) and low 
voltage compexes (18%). RVH pattern was seen only in 10% of  
patients. This showed that ECG findings can be normal in COPD 
patients with Pulmonary hypertension.  
Echocardiographic findings: 
 Most common echo finding among 100 patiens was Left 
ventricular diastolic dysfunction. 80% of patients had left diastolic 
dysfunction. 50% of patients had Pulmonary hypertension. RV 
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dysfunction was seen in 14% patients and LV systolic dysfunction was 
seen in 6% of patients. 
 LV diastolic function was assessed and graded by Doppler 
echocardiography.  Most of the patients had grade I diastolic 
dysfunction (60%). 16 patients had grade II diastolic dysfunction (16%) 
and 4 patients had grade III diastolic dysfunction (4%) 
LV Diastolic dysfunction and COPD: 
 Our study showed that there is high prevalence of Left 
Ventricular diastolic dysfunction in chronic obstructive pulmonary 
disease and there is close association between and LV diastolic 
dysfunction and severity of COPD. LV diastolic dysfunction can also 
occur in early stages (Stage I and II) of COPD. This study showed that 
most of the patient with stage II had mild left diastolic dysfunction. In 
later stages (III&IV), all patients had left ventricular diastolic 
dysfunction and severity of dysfunction also increases. So this study 
showed that there is significant correlation between prevalence of LV 
diastolic dysfunction and severity of COPD.  
LV diastolic dysfunction can occur in COPD patients irrespective 
of age, sex, duration of symptoms and smoking status. This also showed 
that LV diastolic dysfunction can occur even the absence of Pulmonary 
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Hypertension and significant changes in ECG and chest X ray.  The 
study “Prevalence of Left Ventricular diastolic dysfunction in COPD” 
was comparable to studies conducted by Caram LM et al93, Boussuges  
et al94, Rutten et al95, and Funk et al77, Godoy et al.97 
In agreement with our results, Caram LM et al. showed high 
prevalence of LV diastolic function (88%) in COPD and it is associated 
with disease severity.93 
Boussuges et al. found a high prevalence of left ventricular 
diastolic dysfunction in COPD (76%) compared to control (35%)94.  
Rutten et al. and Funk et al. also reported the prevalence above 50%. 
In agreement with our results Godoy et al. showed higher 
prevalence of LVDD among COPD patients which is associated with 
increased disease severity, and the prevalence was 88%97 
. Other factors influence the development of LV diastolic 
dysfunction are 
 Age 
 Smoking 
 Duration of symptoms 
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Age: 
 This study showed that, As the age advances, prevalence of LV 
diastolic dysfunction also increases. So LV diastolic dysfunction was 
more common in older individuals compare to younger individuals. This 
correlation was observed in Ying sum et al. 83 
Smoking: 
 Our study showed that LV diastolic dysfunction can occur even in 
the absence of smoking history. But our study also showed that smoking 
significantly increase the risk of developing LV diastolic dysfunction as 
earlier due to rapid decline in FEV1. 
Duration of symptoms: 
 This study showed that Duration of symptoms and disease also 
significantly affects the development of LV diastolic dysfunction. As 
the duration of symptoms increases, prevalence of diastolic dysfunction 
increases. 
. 
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CONCLUSION 
Following results were concluded from our study: 
 Chronic obstructive pulmonary disease was more commonly seen 
in middle aged patients and rare below the age of 35 years and is 
common in males than females with male to female ratio 4:1 
 Smoking  was the main risk factor for COPD 
 Majority of the patients are in GOLD stage II 
 Most common chest X ray finding was hyper inflated lung fields 
 Half of patients had normal ECG findings 
 Right axis deviation and P-Pulmonale were the common ECG 
findings 
 Mild LV diastolic dysfunction was the most common Echo 
finding 
 There was high prevalence of Left Ventricular diastolic 
dysfunction in COPD patients. 
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 LV diastolic dysfunction can be present even in the absence of 
pulmonary hypertension and it can be observed in early stages of 
COPD. 
 LV diastolic dysfunction can occur even in the absence of 
significant changes in ECG. 
 Significant correlation was observed between LV diastolic 
dysfunction and Age of the patients, smoking status, duration of 
symptoms. 
 There is definite statistical correlation  between LV diastolic 
dysfunction and severity of COPD 
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SUMMARY 
 COPD is a systemic disease and frequently co-exists with 
cardiovascular complications. Left ventricular diastolic dysfunction is 
one of the common cardiac manifestation, highly prevalent in COPD 
patients, which significantly affects the morbidity and mortality 
Left diastolic dysfunction can be asymptomatic or associated with 
heart failure symptoms. Often diastolic heart failure coexists with acute 
exacerbation of COPD and it is very difficult to diagnose and it 
challenges the managing physicians. It is very important to exclude 
decompensated heart failure during COPD exacerbation. 
All patients with COPD should undergo cardiac evaluation by 
echocardiography particularly to assess the LV diastolic function and 
diastolic heart failure can be managed with Cardioselective Beta 
blockers, ACE inhibitors and Diuretics. 
All patients should be educated about Pulmonary Rehabilitation 
Programme including exercise training and smoking cessation, which 
improves the survival of the patient and significantly reduce the co 
morbidities associated with COPD. 
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ANNEXURE 
  
  
 
Name : 
 
Age: 
 
Sex: 
 
Address: 
 
Occupation: 
 
Duration of disease: 
 
Presenting complaints: 
 
Past history: 
 Diabetes Mellitus 
 Hypertension 
 Heart Diseases 
 Chronic Kidney Disease 
 
Smoking history: 
 Smoking duration: 
 Pack years: 
 
General Examination 
 Built 
 Nourishment 
 Height 
 Weight 
 Pallor 
 Icterus 
 Clubbing 
 Cyanosis 
 Pedal edema 
 Lymphadenopathy 
 Jugular venous pulse 
  
VITALS SIGNS: 
   
PR - 
  BP - 
  RR - 
 
SYSTEMIC EXAMINATION 
 
RS Examination: 
CVS Examination: 
Per Abdomen: 
CNS Examination: 
 
INVESTIGATIONS 
 
Chest X ray: 
 Hyperinflated lung fields 
 Prominent Bronchovascular markings 
 
Electrocardiography: 
 P-Pulmonale 
 Right Axis Deviation 
 Right Ventricular Hypertrophy 
 Right Bundle Branch Block 
 Poor Progression of R wave 
 Low voltage complexes 
 Arrhythmias 
 
Pulmonary Function Test: 
  FEV1: 
  FVC: 
  FEV1/FVC: 
  Stage of COPD: 
 
Echocardiography: 
 LV systolic Function: 
 LV Diastolic Function: 
 Pulmonary Hypertension: 
 Dilated RA/RV: 
 RV dysfunction: 
 
 
 
  
 
 
 
 
 
 
Signature of Investigator                                        Signature of the Participant 
 
 
Date: 
Place: 
 
 
 
  
 
  
 
   
   
   
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
Muha;r;rp jfty; jhs; 
  
nrd;id ,uh[pt; fhe;jp muR nghJ kUj;Jtkidapy; mDkjp;f;fg;gLk; 
ehs;gl;l EiuaPuy; milg;G Nehapidg; gw;wpa xU Muha;r;rp eilngw;W 
tUfpwJ. 
 ehs;gl;l EiuaPuy; milg;G Nehapdhy; ,jaj;jpd; ,lJ ntd;l;hpf;fpspy; 
tphptpaf;f gpwo;r;rp Vw;gLtij kpd; xyp ,ija tiuT %yk; mwptij ,e;j 
Muha;r;rpapd; Nehf;fkhFk;. 
  ePq;fSk; ,e;j Muha;r;rpapy; gq;Nfw;f ehq;fs; tpUk;GfpNwhk.;; KbTfis 
my;yJ fUj;Jf;fis ntspapLk; NghNjh my;yJ Muha;rprpapd; NghNjh 
jq;fsJ ngaiuNah my;yJ milahsq;fisNah ntspaplkhl;Nlhk; 
vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;; 
 ,e;j Muha;r;rpapy; gq;Nfw;gJ jq;fSila tpUg;gj;jpd; Nghpy; jhd; 
,Uf;fpwJ.  NkYk; ePq;fs; ve;NeuKk; ,e;j Muha;r;rpapypUe;J gpd;thq;fyhk; 
vd;gijAk; njhptpj;Jf; nfhs;fpNwhk;;. 
 ,e;j rpwg;Gg; ghpNrhjidfspd; KbTfis Muha;r;rpapd; NghJ my;yJ 
Muha;r;rpapd; Kbtpy; jq;fSf;F mwptpg;;Nghk; vd;gijAk; njhptpj;Jf; 
nfhs;fpNwhk;. 
 
 
Muha;r;rpahsh; ifnahg;gk;    gq;Nfw;ghsh; ifnahg;gk; 
 
 
Njjp: 
 
 
 
 
 
 
  
ஆராய்ச்சி ஒப்புதல் கடிதம் 
ஆராய்ச்சி தலைப்பு: 
 நாள்பட்ட நுலரயீரல் அலடப்பு நநாயினால் இதயத்தின் இடது 
வென்ட்ரிக்கிளில் ெிரிெியக்க பிறழ்ச்சி ஏற்படுெலத பற்றிய ஆராயச்சி. 
வபயர்:       நததி: 
ெயது:      உள்நநாயாளி எண்: 
பால்:       ஆராய்ச்சி நசர்க்லக எண்: 
 இந்த ஆராய்ச்சியின் ெிெரங்களும் அதன் நநாக்கங்களும் 
முழுலையாக எனக்கு வதளிொக ெிளக்கப்பட்டது. எனக்கு 
ெிளக்கப்பட்ட ெிஷயங்கலள நான் புரிந்து வகாண்டு எனது சம்ைதத்லத 
வதரிெிக்கிநறன். 
இந்த ஆராய்ச்சியில் பிறரின் நிர்பந்தைின்றி என் வசாந்த 
ெிருப்பத்தின்ப்நபரில் பங்கு வபறுகிநறன். இந்த ஆராய்ச்சியில் இருந்து 
நான் எந்நநரமும் பின் ொங்கைாம் என்பலதயும் அதனால் எந்த 
பாதிப்பும் ஏற்படாது என்பலதயும் நான் புரிந்து வகாண்நடன். 
நான் இந்த ஆராய்ச்சியின் ெிபரங்கலளக்வகாண்ட  ஆராய்ச்சி 
தகெல் தாலள வபற்றுக்வகாண்நடன்.  
இதன் மூைம் எந்த பின் ெிலளவும் ஏற்படாது என்று ைருத்துெர் 
மூைம் வதரிந்துக்வகாண்டு இந்த ைருத்துெ ஆராய்ச்சியில் என்னலன 
நசர்த்துக்வகாள்ள சம்ைதம் வதரிெிக்கிநறன். 
 
 
 
ஆராய்ச்சியாளர் லகவயாப்பம்             பங்நகற்ப்பாளர் லகவயாப்பம் 
 
நாள்: 
இடம்: 
 

  
KEY TO MASTER CHART 
 A               –     Absent  
 ECG            –   Electrocardiogram 
 F                –     Female  
FEV1         –     Forced   Expiratory Volume in one second 
FVC          –     Forced Vital Capacity 
 LVDD        –    Left ventricular diastolic dysfunction 
 LVSD        –     Left ventricular systolic dysfunction 
 M              –      Male  
 P                –      Present  
 PFT             –    Pulmonary Function Test   
 PHT            –    Pulmonary hypertension 
 PPRW        –     Poor Progression of R wave 
RA            –      Right Atrium 
 RAD          –     Right axis deviation 
 RBBB        –     Right Bundle Branch Block 
RV            –      Right Ventricle 
 RVH          –     Right Ventricular Hypertrophy 
RVH         –      Right Ventricular Hypertrophy 
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1 55 M 49012 15 8 <0.7 47 III P A P A P A A A A II P P A
2 49 M 56897 10 3 <0.7 55 II P A A A A A A A A I A A A
3 62 M 54321 12 2 <0.7 65 II P A A A A P P A A I P A A
4 48 M 50098 9 1 <0.7 83 I A P A A A A A A A A A A A
5 62 F 55471 0 4 <0.7 75 II P A A A A A P P A I P A A
6 69 M 57912 16 12 <0.7 27 IV P A P A P A P A P III P P P
7 51 M 56823 11 6 <0.7 59 II A P A A A A A A A I A A A
8 54 F 59864 0 9 <0.7 41 III A P P P P A A A A I P P A
9 65 M 58734 17 7 <0.7 36 III P A A A P P P P A I A A A
10 57 M 57908 22 13 <0.7 28 IV P A P P P A A A A II P P P
11 45 M 57143 5 2 <0.7 75 II A P A A A A A A A A A A A
12 70 M 55876 20 15 <0.7 40 III P A A A A A P P A II P P A
13 52 F 56002 0 7 <0.7 85 I A P A A A A A A A A A A A
14 58 M 56405 10 3 <0.7 83 I A P A A A A A A A A A A A
15 65 M 50834 16 7 <0.7 29 IV P A P A P P P A A I P P P
16 67 M 51890 12 9 <0.7 61 II P A A A P A A A A I A A A
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17 51 M 52675 6 1 <0.7 70 II P A A A A A A A A I A A A
18 59 M 53097 11 4 <0.7 48 III A P P A P A A A A I P P A
19 65 M 54771 9 7 <0.7 34 III P A A A A A A A A II P A A
20 61 M 58234 10 4 <0.7 57 II P A A A A A A A A I A A A
21 67 F 60932 0 6 <0.7 42 III P A P A P P P P A I P A A
22 54 M 61234 7 2 <0.7 67 II A P A A A A P A A I A A A
23 55 M 60456 9 1 <0.7 76 II P A P P A A A A A I P A A
24 70 M 61935 21 4 <0.7 26 IV P A P A P A P P A III P P P
25 59 M 59006 14 3 <0.7 85 I P A A A A A A A A I A A A
26 72 F 56456 0 8 <0.7 40 III P A A A A A P P P II P A A
27 53 M 62345 20 5 <0.7 59 II P A A A A A A A A I A A A
28 64 M 66879 11 12 <0.7 33 III P A A A A A A A A I A A A
29 49 M 65106 7 6 <0.7 61 II A P P A P A A A A A P P A
30 60 F 66479 0 2 <0.7 89 I A P A A A A A A A A A A A
31 45 M 59487 10 3 <0.7 39 III P A P A P A A A A I P P A
32 47 M 58146 7 5 <0.7 76 II P A A A A A A A A I A A A
33 55 M 64501 10 4 <0.7 67 II A P A A A A A A A I A A A
34 46 M 66305 5 2 <0.7 89 I A P A A A A A A A A A A A
35 50 F 62348 0 5 <0.7 41 III P A A A A A P P A I P A A
36 71 M 63209 25 15 <0.7 28 IV P A P P P A A A P II P P P
37 65 M 64025 18 12 <0.7 25 IV P A P A P P P P A II P P P
38 59 M 65754 11 9 <0.7 74 II A P A A P A A A A A P A A
39 58 F 70001 0 8 <0.7 47 III P A A A A A A A A I P A A
40 43 M 69806 7 3 <0.7 68 II A P A A A A A A A I A A A
41 68 M 60407 0 3 <0.7 85 I A P A A A A A A A A A A A
42 39 M 68900 0 1 <0.7 84 I A P A A A A A A A A A A A
43 44 M 67608 12 2 <0.7 67 II P A A A A A A A A I A A A
44 59 F 67100 0 13 <0.7 29 IV P A P P P A A A A II P P P
45 65 M 68340 15 8 <0.7 71 II P A A A A A A A A I A A A
46 57 M 68934 12 5 <0.7 40 III P A A A A A A A A I A A A
47 53 M 69403 8 4 <0.7 39 III P A P A A P A A A I P P A
48 68 M 70265 9 10 <0.7 73 II A P A A A A A A A I A A A
49 70 M 70864 15 7 <0.7 70 II P A A A A A A A A I P P A
50 53 F 63786 0 3 <0.7 43 III P A A A A A P P A I P A A
51 46 M 71200 5 2 <0.7 75 II A P A A A A A A A A A A A
52 71 M 71508 20 15 <0.7 40 III P A A A A A P P P II P P A
53 51 F 71945 0 7 <0.7 85 I A P A A A A A A A A A A A
54 59 M 73206 11 3 <0.7 83 I A P A A A A A A A A A A A
55 66 M 73145 15 7 <0.7 29 IV P A P A P P P A A I P P P
56 68 F 73897 0 6 <0.7 42 III P A P A P P P P A I P A A
57 55 M 73502 8 2 <0.7 67 II A P A A A A P A A I A A A
58 54 M 72845 10 1 <0.7 76 II P A P P A A A A A I P A A
59 71 M 72108 20 4 <0.7 26 IV P A P A P A P P A III P P P
60 58 M 72765 15 3 <0.7 85 I P A A A A A A A A I A A A
61 46 M 74002 9 3 <0.7 39 III P A P A P A A A A I P P A
62 48 M 74354 7 5 <0.7 76 II P A A A A A A A A I A A A
63 54 M 74634 11 4 <0.7 67 II A P A A A A A A A I A A A
64 49 M 75102 6 2 <0.7 89 I A P A A A A A A A A A A A
65 51 F 75492 0 5 <0.7 41 III P A A A A A P P A I P A A
66 69 M 76546 0 3 <0.7 85 I A P A A A A A A A A A A A
67 40 M 77095 0 1 <0.7 84 I A P A A A A A A A A A A A
68 43 M 77234 11 2 <0.7 67 II P A A A A A A A A I A A A
69 59 F 77850 0 13 <0.7 29 IV P A P P P A A A A II P P P
70 64 M 76098 14 8 <0.7 71 II P A A A A A A A A I A A A
71 56 M 76438 16 8 <0.7 48 III P A P A P A A A A II P P A
72 48 M 78609 12 3 <0.7 56 II P A A A A A A A A I A A A
73 61 M 79256 11 2 <0.7 65 II P A A A A P P A A I P A A
74 49 M 79699 8 1 <0.7 82 I A P A A A A A A A A A A A
75 63 F 74687 0 4 <0.7 74 II P A A A A A P P A I P A A
76 72 M 71204 24 15 <0.7 29 IV P A P P P A A A P II P P P
77 66 M 80789 19 12 <0.7 26 IV P A P A P P P P A II P P P
78 58 M 80384 12 9 <0.7 73 II A P A A P A A A A A P A A
79 59 M 80408 13 8 <0.7 48 III P A A A A A A A A I P A A
80 44 F 80957 0 3 <0.7 69 II A P A A A A A A A I A A A
81 58 M 81209 11 5 <0.7 41 III P A A A A A A A A I A A A
82 54 M 81606 9 4 <0.7 38 III P A P A A P A A A I P P A
83 69 M 81456 10 10 <0.7 72 II A P A A A A A A A I A A A
84 71 M 82345 16 7 <0.7 69 II P A A A A A A A A I P P A
85 54 M 82609 17 3 <0.7 44 III P A A A A A P P A I P A A
86 68 M 82991 15 12 <0.7 28 IV P A P A P A P A P III P P P
87 50 M 83035 13 6 <0.7 58 II A P A A A A A A A I A A A
88 53 F 83789 0 9 <0.7 42 III A P P P P A A A A I P P A
89 66 M 83125 16 7 <0.7 35 III P A A A P P P P A I A A A
90 58 M 84687 23 13 <0.7 27 IV P A P P P A A A A II P P P
91 68 M 84890 14 9 <0.7 60 II P A A A P A A A A I A A A
92 52 M 85209 7 1 <0.7 69 II P A A A A A A A A I A A A
93 58 F 85867 0 4 <0.7 49 III A P P A P A A A A I P P A
94 64 M 86239 8 7 <0.7 35 III P A A A A A A A A II P A A
95 62 M 86098 11 4 <0.7 58 II P A A A A A A A A I A A A
96 71 M 87781 16 8 <0.7 41 III P A A A A A P P A II P A A
97 54 M 89004 21 5 <0.7 68 II P A A A A A A A A I A A A
98 65 M 76662 12 12 <0.7 32 III P A A A A A A A A I A A A
99 48 M 90823 8 6 <0.7 60 II A P P A P A A A A A P P A
100 61 F 74567 0 2 <0.7 88 I A P A A A A A A A A A A A
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
